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Hypericum  species,  Hypericaceae,  are  recognized  as  a source  of therapeutical  agents.  Puriﬁed  fractions
and  isolated  compounds  have  been  shown  antimicrobial  activity.  As  the  indiscriminate  use  of  antifungals
and  the  increase  of infections  caused  by emerging  species  are  leading  to the  search  of new  alterna-
tive  treatments,  the  aim  of this  study  was to continue  the  study  with  Hypericum  carinatum  Griseb.
lipophilic  fraction,  rich  in  phloroglucinol  derivatives,  investigating  the  effect  of  its  association  with ﬂu-
conazole  against  emerging  yeasts  (Candida  krusei,  C.  famata,  C. parapsilosis  and  Cryptococcus  neoformans).
The  synergistic  activity  between  H.  carinatum  lipophilic  fraction  and  ﬂuconazole  was  assessed  by  two
methodologies  for multiple  dose–response  analysis:  checkerboard  and  isobologram.  Regarding  syner-
gistic experiments,  the  effect  of the association  was  higher  than  the  effect  of ﬂuconazole  alone  against
Candida  krusei  and  C.  famata  isolates  (MIC ﬂuconazole  decreased  about  eight  and  four folds,  respectively),
suggesting  that,  somehow,  H. carinatum  lipophilic  fraction  compounds  are  facilitating  the  action  of  thisynergistic activity
drug.  On  the  other  hand,  when  tested  against  Cryptococcus  neoformans  and  C. parapsilosis,  ﬂuconazole
showed  better  results  than the  association.  Thus,  against  Candida  krusei  and  C. famata, the  lipophilic
fraction  of  H.  carinatum  was able  to reduce  the MIC values  of ﬂuconazole  and  could  be  considered  as a
potential  alternative  to be  used  against  emerging  yeast  species.
© 2016  Sociedade  Brasileira  de  Farmacognosia.  Published  by  Elsevier  Editora  Ltda.  This  is an  open
he CCaccess  article  under  t
ntroduction
Fungal infections are associated with high morbidity and mor-
ality rates. In the last decades, emerging fungal infections, also
alled opportunistic infections, have drawn attention due to the
igh number of immunocompromised patients affected (Silva
t al., 2012). Some species of Candida and Cryptococcus, previously
onsidered nonpathogenic, are now recognized as opportunistic
athogens responsible for deep-seated mycoses (Vandeputte et al.,
012; Alcazar-Fuoli and Mellado, 2014).
The high incidence of infection by Candida species is due to many
actors such as imunossupressive therapies, invasive surgical pro-
edures and use of broad-spectrum antibiotics (Pfaller et al., 2012).
andida albicans is still the most prevalent species but infections
aused by non-Candida albicans (NCA) have signiﬁcantly increased,
ringing even more worrying scenario due to high resistance to
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antifungal exhibited by these microorganisms (Pfaller et al., 2010,
2012). Since the epidemiology of these fungal infections is currently
changing, new alternatives are needed in case of antifungal therapy
failure (Alcazar-Fuoli and Mellado, 2014).
Because of yeasts inconstant susceptibility proﬁles and lack of
different molecular targets, drug combinations appear as a strategy
for therapy due to the multiplicity of targets (Musiol et al., 2014).
The main advantage of these combinations is the synergistic inter-
action, in which the antifungal activity is better than the individual
effects of each compound.
Plants from genus Hypericum,  Hypericaceae, are an impor-
tant source of therapeutic agents. Puriﬁed fractions and isolated
compounds have shown antibacterial and antifungal activities
(Barros et al., 2013; Dulger and Dulger, 2014). Barros et al. (2013)
have reported the antifungal activity of lipophilic extracts of ﬁve
Hypericum species (H. carinatum,  H. caprifoliatum, H. linoides, H.
myriathum and H. polyanthemum) against several emerging fun-
gal strains, with better results for H. carinatum.  According to these
authors, dimeric phloroglucinol derivatives (uliginosin B, hyper-
brasilol B and japonicin A), present in lipophilic fractions could
ora Ltda. This is an open access article under the CC BY-NC-ND license (http://
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e responsible for the antifungal activity showed by Hypericum
pecies. Other compounds with phloroglucinol pattern such as ben-
opyrans and benzophenones also showed antifungal activity.
Due to the indiscriminate use of antifungals and the increase
f infections caused by emerging species new alternative treat-
ents are necessary. Thus, the aim of this work was to continue
he study with Hypericum carinatum Griseb. lipophilic fraction
LF), investigating the effect of its association with ﬂuconazole
gainst the emerging yeasts Candida krusei,  C. famata,  C. parapsilosis
nd Cryptococcus neoformans. The synergistic activity between LF
nd ﬂuconazole was assessed by two methodologies for multiple
ose–response analysis: checkerboard and isobologram.
aterials and methods
lant material
Aerial parts of Hypericum carinatum Griseb., Hypericaceae, were
ollected in Rio Grande do Sul, Brazil, in December of 2009. Voucher
pecimens are deposited in the herbarium of Federal Univer-
ity Rio Grande do Sul (ICN). Plants collection was  authorized by
BAMA (Brazilian Institute of Ambient Media and Renewable Nat-
ral Resources) (n◦ 003/2008, protocol: 02000.001717/1008-60).
ipophilic fraction preparation
The dried and powdered plant material (ca. 500 g) was  extracted
ith hexane at room temperature. The extract was  pooled, evap-
rated to dryness under reduced pressure, and the epicuticular
axes were removed by acetone treatment. The lipophilic fraction
LF) was stored at −20 ◦C until biological and chemical evaluation.
LF was analyzed by HPLC using a Shimadzu 600 pump (LC-
AD) and a Shimadzu SPD-10A dual absorbance detector. The
eparations were carried out with an isocratic solvent system
60% acetonitrile:40% water) to benzophenones determination
nd (95% acetonitrile, 5% water, 0.01% triﬂuoroacetic acid) to
hloroglucinol derivatives using a Waters Nova-Pack C18 column
4 m,  3.9 mm × 150 mm)  adapted to a Waters Nova-Pack C18 60 A˚
3.9 mm × 20 mm)  guard column. The ﬂow rate was 1 ml/min, the
etector sensitivity was 1.0 Aufs, and the detection was performed
t 270/220 nm at room temperature.
Constituents were identiﬁed by comparison with the retention
imes of the authentic samples and co-injection of isolated com-
ounds. The yields were expressed in % (weight compound per
eight dry extract) as mean of two injections.
F toxicity
The experimental protocol was approved by Local Ethical
ommittee (Protocol 23081, UNIPAMPA). The toxicity of LF was
valuated by cell viability test and comet assay, according to Güez
t al. (2012), analyzing three different fraction concentrations: 500,
50 and 100 g/ml.
ungal strains
Four resistant strains to ﬂuconazole were used in this study.
nterpretative criteria of resistance were used according to break-
oints from M27-S4 document (CLSI, 2012) to Candida and
ccording to Espinel-Ingroff et al. (2012) to Cryptococcus neofor-
ans. All strains are deposited in the Mycology Collection of Federal
niversity of Rio Grande do Sul, Brazil: Candida famata (RL23) ori-
inates from hemoculture, C. krusei (CK03) from National Program
f Quality Control, C. parapsilosis (RL11) from urine and Crypto-
occus neoformans (HCCRY 01) from environment (environmentalarmacognosia 27 (2017) 118–123 119
pathogenic). C. krusei ATCC 6258 was  included as control in the
susceptibility testing.
Antifungal activity
The screening for antifungal activity was  carried out with a
concentration of 500 g/ml. In order to achieve the test con-
centration, samples were solubilized with dimethyl sulfoxide 2%
(DMSO) and sabouraud dextrose broth (SDB). Further, the mini-
mal  inhibitory concentration (MIC) was  determined by the broth
microdilution method according to M27-A3 protocol (CLSI, 2008).
The MIC  was  deﬁned as the lowest concentration of LF in which
the microorganism tested did not demonstrate visible growth. In
microdilution experiments, samples were solubilized with DMSO
2% and RPMI-MOPS medium (RPMI 1640 medium) containing l-
glutamine, without sodium bicarbonate buffered to pH 7.0 with
0.165 mol/l of MOPS buffer. The concentrations of LF ranged from
1.9 to 500 g/ml and all experiments were carried out in duplicate.
Control with DMSO 2% was previously performed.
Association studies
Checkerboard assay
The effect of ﬂuconazole combined with LF was evaluated in
quadruplicate using the checkerboard method (Johnson et al., 2004)
with slightly modiﬁcations. The ﬂuconazole ﬁnal concentrations
ranged from 0.5 to 32 g/ml for C. famata and C. neoformans,
and 4 to 64 g/ml for C. krusei and C. parapsilosis. On the other
hand, the concentration of LF ranged from 31.25 to 250 g/ml
for C. famata and C. neoformans and 4 to 250 g/ml for C. kru-
sei and C. parapsilosis. Plates were incubated at 37 ◦C for 48 h
and then, the tetrazolium salt 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) was used to assess the fungal
cell viability. Interaction was  evaluated algebraically by determin-
ing the fractional inhibitory concentration index (FICI) deﬁned as
the sum of the MIC  of each drug in combination, divided by the
MIC  of the drug used alone. An FICI ≤ 0.5 is considered synergistic;
>0.5 and ≤1 additive; >1 and ≤4 indifferent, and >4 antagonistic
(Kontoyiannis and Lewis, 2003).
Isobologram
The isobologram was  performed with the association of LF and
ﬂuconazole against C. krusei (CK03) and C. parapsilosis (RL11).
A curve concentration-effect of LF or ﬂuconazole was deter-
mined with logarithmic concentrations, in order to obtain the IC50
(inhibitory concentration 50%) by non-linear regression. Then, with
these results, curves concentration-effect of association were also
performed by non-linear regression (Tallarida, 2006, 2007). The
proportion of combinations is demonstrated in Table 1.
Theoretical additive curves (IC50 add) were calculated to each
combination according the equation:
Conc.add = f × Conc. ﬂuconazole + (1 − f ) × Conc. Fraction
where, Conc.ﬂuconazole and Conc.Fraction represent the equi-
effective concentration of each treatment alone and f is the fraction
of each sample that composes the active concentration of associ-
ation (in this study two f values 0.5 (50:50) and 0.7 (70:30) were
used). Conc.add is the total concentration and its variance was cal-
culated by this equation:
Var IC50add = f ∗2 × Var IC50ﬂuconazole + (1 − f )∗2
× Var IC50 fraction
From these variances, conﬁdence intervals were calculated
according to the proportion of each sample in the association.
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Table  1
Proportion of combinations used in isobologram studies.
Yeasts strains Fluconazole concentration
(%IC50)
LF concentration
(%IC50)
Candida krusei
CK03
50 50
25 25
12.5  12.5
6.25 6.25
3.125 3.125
70  30
35 15
17.5 7.5
8.75 3.75
4.38 1.875
2.19 0.938
1.095 0.496
Candida
parapsilosis RL11
50 50
25 25
12.5  12.5
6.25 6.25
3.125 3.125
70  30
35 15
17.5  7.5
8.75 3.75
4.38 1.875
2.19 0.938
1.095 0.496
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candida parapsilosis RL11: IC50 ﬂuconazole: 26.55 g/ml and IC50 LF: 174.7 g/ml;
andida krusei CK03: IC50 ﬂuconazole: 35.58 g/ml and IC50 LF: 35.76 g/ml.
esides, the interaction magnitude was calculated through inter-
ction index (), following the formula:
b = dose ﬂuconazole IC50 mixture + dose fraction IC50 mixture
The interaction index is an indicator of the potency of the asso-
iation. Values next to 1 indicate additive interaction; values higher
han 1, antagonistic interaction, and values lower than 1, synergistic
nteraction (Grabovsky and Tallarida, 2004).
tatistical analysis
Checkerboard and toxicity data were evaluated using one-way
nalysis of variance (ANOVA) followed by Tukey’s test (Sigma
tat 3.2 software, Jandel ScientiﬁcCorporation®). In checkerboard,
he difference between antifungal activity of ﬂuconazole alone
nd in combination with LF was evaluated. Differences were con-
idered statistically signiﬁcant at p < 0.05. The isobologram data
ere performed with Student t test, where IC50 mixture is sig-
iﬁcantly shorter than IC50 calculated (IC50 add) to a determined
ombination, there is a synergistic interaction (Codd et al., 2008).
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ig. 1. (A) DNA damage index determined by comet assay and (B) Cell viability in leucocyt
hosphate buffered saline (PBS) was used as negative control and hydrogen peroxide (10
ontrol in these assays. Vertical bars are mean ± SD of three different replicates. Differentarmacognosia 27 (2017) 118–123
The non-linear regression analysis was performed using GraphPad
Prism® version 4.02.
Results and discussion
Chemical analysis
HPLC analysis were carried out to quantify the major con-
stituents of LF. As demonstrated by Barros et al. (2013), the
main constituents of H. carinatum lipophilic fraction are the
phloroglucinol derivative uliginosin B (1) (1.65 ± 0.08%) and the
benzophenones cariphenone A (2) (0.08 ± 0.001%) and cariphenone
B (3) (0.58 ± 0.009%), conﬁrming the previous results.
LF toxicity
The investigated fraction (LF) did not show toxic effects at the
concentration used (250 g/ml) in association studies as demon-
strated in Fig. 1. According to these results, the concentration of
500 g/ml showed DNA damage (Fig. 1A) as well as reduced cellu-
lar viability (Fig. 1B). Therefore, the higher LF concentration used
at this study (250 g/ml) is considered safe by these two toxicity
methodologies.
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es for Hypericum carinatum lipophilic fraction (LF) in three different concentrations.
 M)  (H2O2) as positive control in both experiments. DMSO 2% was used as diluent
 letters represents signiﬁcant differences at p < 0.05 (Tukey test).
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Table  2
Minimal inhibitory concentration (MIC) of Hypericum carinatum lipophilic fraction
(LF) against emerging yeasts strains.
Species Strains MICaLF
Candida famata RL23 250
Candida krusei CK03 >1000
Candida parapsilosis RL11 250
A
t
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sCryptococcus neoformans HCCRY01 125
a MIC  (g/ml): minimal inhibitory concentration.
ntifungal activity
Concerning the antifungal capacity, LF was  capable of inhibit
he fungal growth in a moderate way (Table 2). This capacity may
e attributed to the presence of dimeric phloroglucinol deriva-
ives as uliginosin B (1) and the benzophenones cariphenone A (2)
nd cariphenone B (3). These results are in accordance with those
escribed by Barros et al. (2013).
ssociation studies
The results obtained in the checkerboard analysis (Fig. 2) are
nteresting, since LF was capable of reducing the ﬂuconazole MIC
alues for all species tested. For C. neoformans, C. krusei and C.
arapsilosis the ﬂuconazole MIC  decreased about eight fold (% Cell
amage = 75.6%, ICIF = 0.375; % Cell damage = 91.2%, ICIF = 0.25 and
 Cell damage = 71.3%, ICIF = 0.5, respectively), while for C. famata
his value was about four fold (% Cell damage = 94.4%, ICIF = 0.5).
evertheless, for C. neoformans and C. parapsilosis, the ﬂuconazole
IC  was capable of achieving a higher cell damage in comparision
ith association. Therefore, the use of the combinations is only jus-
iﬁed when decrease of drug dose is needed, especially in cases
here the microorganisms are resistant to this azole.
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Concerning the isobologram analysis the curves concentration
effect of each compound tested (ﬂuconazole and LF) showed IC50
values of 35.58 g/ml and 35.76 g/ml for C. krusei and 26.55 g/ml
and 174.7 g/ml for C. parapsilosis, respectively. It is important to
note that this methodology was not applied to C. famata and Cryp-
tococcus neoformans due to the impossibility of to construct dose
response curves with ﬂuconazole alone.
The results obtained in the isobologram (Fig. 3), are in agreement
with those obtained by the checkerboard analysis, where synergis-
tic effect was found to both species tested (C. krusei CK 03 and C.
parapsilosis RL11). The interaction index () was  less than 1 for
all proportions tested for C. krusei (50:50 = 0.36; 70:30 = 0.57) and
for C. parapsilosis (50:50 = 0.79; 70:30 = 0.75). However, this index
against C. parapsilosis was  closer to 1, indicating a probable pres-
ence of additive effect instead of synergistic, corroborating with the
ICIF (0.5) found for this association in the checkerboard analysis.
The increased incidence of systemic infections caused by NCA
species and the high mortality rates due to acquired resistance
against drugs current utilized is worrisome, as well as the high
incidence of polymicrobial fungal infections (Ruhnke, 2014; Triﬁlio
et al., 2015). Therefore, the association between different com-
pounds could be an excellent strategy to reduce the drug doses,
and thus, achieve the resistance reversion.
There are two hypotheses to lipophilic fraction of H. carinatum
decreases the MIC  of ﬂuconazole. The ﬁrst could be related to the
general action mechanism of phenolic compounds, change the fun-
gal dimorphism (Zhang et al., 2011) and/or opening of membrane
ionic channels (Rao et al., 2010) both found for C. albicans. The sec-
ond hypothesis lies in the fact that some benzophenones are able
to block the cytochrome P-450 (Podust et al., 2007). Nevertheless,
since it is a fraction, the synergistic effects of the bioactive com-
pounds mixture could be responsible by increasing the effectivity
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d ﬂuconazole against Cryptococcus neoformans HCCRY01 (MICFluco = 32 g/ml,
= 8 g/ml, MICLF = 250 g/ml, Association = MIC/4Fluco:MIC/4LF) (B), Candida krusei
d Candida parapsilosis RL 11 (MICFluco = 32 g/ml, MICLF = 250 g/ml, Associa-
. Vertical bars are mean ± SD of four different replicates. Different letters represents
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dditive  equi-effective Concentration (50:50) and () concentration equi-effective 
f itself, and then, the antifungal effect is achieved by a sum of
echanisms (Wagner, 2011).
Some studies report association between extracts and antifun-
al drugs such as essential oils in association with ketoconazole
gainst several fungal species (Giordani et al., 2004) and benzophe-
one enriched fraction from Brazilian red propolis with ﬂuconazole
nd anidulafungin against C. parapsilosis and C. glabrata (Pippi et al.,
015). On the other hand, many studies have demonstrated the
ssociation between plant metabolites and antifungal drugs against
andida species. For example, the association of the tannin puni-
alagin and ﬂuconazole against C. albicans and C. parapsilosis (Endo
t al., 2010) and ﬂavonoids (catechin, quercetin and epigallocat-
chin gallate) associate with ﬂuconazole against C. tropicalis (Da
ilva et al., 2014).
There are no doubts that combined therapy between LF and ﬂu-
onazole is beneﬁc, but further studies must be performed in order
o determine the nature of this interaction. The analysis of isolated
ompounds of this fractions alone and/or combined with ﬂucona-
ole is needed aiming to standardize this association in cases where
he monotherapy with ﬂuconazole is ineffective.
onclusion
The results of this study reinforce the use of Hypericum species
s source of products with biological importance. Association
tudies are very signiﬁcant, especially in emerging fungi, which
re worldwide distributed and frequent causes of infections in
mmunocompromised patients. The lipophilic fraction of H. car-
natum was able to reduce the MIC  of ﬂuconazole, probably by
acilitating the access of the drug within the fungal cell. These
esults are important due to the increasing resistance of emerg-
ng yeast species to available drugs used for a variety of fungal
nfections and the exploration of potential alternative therapeutic
ources for multidrug therapy.
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